期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/ijms22073326
关键词
molecular therapy; junctional epidermolysis bullosa; type XVII collagen; splice mutation; antisense oligonucleotides; exon skipping; topical therapy; liposomes
资金
- DEBRA Southern Tyrol
- DEBRA Austria
Intermediate junctional epidermolysis bullosa caused by mutations in the COL17A1 gene is a rare disease with heterogeneous mutations, making therapy development challenging. However, the use of AON to induce exon skipping shows promise as a personalized treatment approach for this condition.
Intermediate junctional epidermolysis bullosa caused by mutations in the COL17A1 gene is characterized by the frequent development of blisters and erosions on the skin and mucous membranes. The rarity of the disease and the heterogeneity of the underlying mutations renders therapy developments challenging. However, the high number of short in-frame exons facilitates the use of antisense oligonucleotides (AON) to restore collagen 17 (C17) expression by inducing exon skipping. In a personalized approach, we designed and tested three AONs in combination with a cationic liposomal carrier for their ability to induce skipping of COL17A1 exon 7 in 2D culture and in 3D skin equivalents. We show that AON-induced exon skipping excludes the targeted exon from pre-mRNA processing, which restores the reading frame, leading to the expression of a slightly truncated protein. Furthermore, the expression and correct deposition of C17 at the dermal-epidermal junction indicates its functionality. Thus, we assume AON-mediated exon skipping to be a promising tool for the treatment of junctional epidermolysis bullosa, particularly applicable in a personalized manner for rare genotypes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据